Diethylstilbestrol exposure.
Level 5 - mechanism / opinion, no new human data
Narrative clinical review without systematic review methodology reported
What was done
The authors reviewed clinical findings on the long-term health effects of maternal and in utero diethylstilbestrol (DES) exposure and outlined clinical screening and management recommendations for exposed individuals.
What was found
The abstract reports no numerical effect sizes or risk estimates. It qualitatively reports that women taking DES during pregnancy have a slightly higher risk of breast cancer. Females exposed in utero face increased risks of clear cell adenocarcinoma of the cervix/vagina, structural reproductive tract anomalies, infertility, spontaneous abortion, ectopic pregnancy, and preterm delivery, though most successfully deliver. Males exposed in utero have an increased incidence of genital abnormalities and a potentially elevated risk of prostate and testicular cancer. Recommended surveillance includes digital vaginal/cervical palpation, colposcopic evaluation, annual cytology, and routine male urogenital screening.
Why it matters
It provides clinical surveillance guidance for primary care physicians managing aging cohorts exposed to DES decades after its withdrawal.
Limits
The abstract describes a narrative review rather than a systematic review or primary study. No sample sizes, quantitative risk metrics, or formal study selection criteria are reported.
Cited by
- supports Diethylstilbestrol (DES) taken during pregnancy caused cancer in children born to those women.